Related Experiment Videos
Vasopeptidase inhibitors in heart failure
Adelle Dawson1, Allan D Struthers
1Department of Clinical Pharmacology Therapeutics, University of Dundee, Ninewells Hospital, Dundee, Scotland.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|February 4, 2003
Summary
Vasopeptidase inhibitors (VPIs) show promise for hypertension but their benefit in heart failure is unclear. Recent trials suggest VPIs may not offer advantages over existing ACE inhibitors for chronic heart failure treatment.
Area of Science:
- Cardiovascular Pharmacology
- Drug Development
- Clinical Therapeutics
Background:
- Vasopeptidase inhibitors (VPIs) combine angiotensin-converting enzyme (ACE) inhibition with natriuretic peptide breakdown inhibition.
- VPIs are theoretically beneficial for hypertension and heart failure.
- Efficacy in hypertension is established, but heart failure data is conflicting.
Purpose of the Study:
- To review the literature on VPIs in heart failure.
- To discuss potential reasons for lack of observed benefit over ACE inhibitors.
- To evaluate the role of VPIs in chronic heart failure management.
Main Methods:
- Literature review of VPIs in heart failure.
- Analysis of pre-clinical and clinical study results.
- Examination of data from the OVERTURE trial.
Main Results:
- VPI efficacy in hypertension is well-documented.
- Numerous small studies on VPIs in heart failure yielded conflicting results.
- The OVERTURE trial indicated omapatrilat is not a first-line therapy for chronic heart failure.
Conclusions:
- The benefit of VPIs in heart failure remains uncertain.
- Further research is needed to understand VPIs' role in heart failure.
- ACE inhibitors may remain the preferred treatment for chronic heart failure.